Wilex www.wilex.de 
WILEX AG是一家生物制藥公司，總部在德國慕尼黑。公司專注于腫瘤學(xué)，開發(fā)用于各類癌癥的針對性檢測和靶向治療的、基于抗體和小分子的診斷和治療候選產(chǎn)品。WILEX Inc.除了生產(chǎn)、營銷生物標(biāo)記檢測試劑以外，其子公司Heidelberg Pharma GmbH還提供臨床前合同研究服務(wù)和一種抗體藥物螯合物(ADC)技術(shù)平臺。其商業(yè)模式包含研究和產(chǎn)品開發(fā)以及這些活動的商業(yè)化。我們的客戶和合作伙伴包括領(lǐng)先的國際性制藥公司。WILEX AG在法蘭克福證券交易所掛牌上市。ISIN DE0006614720 / WKN 661472 /代碼WL6。
 
WILEX Inc.是德國WILEX AG的全資美國子公司，采用Oncogene Science這一品牌名稱生產(chǎn)、推廣和銷售基于血清的腫瘤蛋白診斷試劑和各類生物標(biāo)記檢測試劑。其產(chǎn)品陣容包括酶聯(lián)免疫吸附檢測(ELISA)和免疫組織化學(xué)(IHC)檢測。為了達(dá)到為世界各地癌癥患者的治療方案提供支持的目的，WILEX Inc.提供用于測量腫瘤基因、生長因子受體(HER-2/neu, EGFr)、蛋白酶和蛋白酶抑制劑(uPA, PAI-1, TIMP-1)以及缺氧標(biāo)記(CA IX)的生物標(biāo)記檢測試劑。新款CA IX IHC是一種1類IVD檢測，除此以外，WILEX Inc.還提供唯一獲得FDA批準(zhǔn)的測量血清HER-2/neu水平的IVD ELISA，HER-2/neu用于轉(zhuǎn)移性乳腺癌女性患者的處治和監(jiān)測。WILEX Inc.總部位于美國馬薩諸塞州劍橋市，同時提供GMP和ISO認(rèn)證的生產(chǎn)服務(wù)。進(jìn)一步信息，請訪問www.oncogene.com。

WILEX

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company develops diagnostic and therapeutic product candidates for the specific detection and targeted treatment of various types of cancer based on antibodies and small molecules. Beside the manufacturing and marketing of the biomarker tests from WILEX Inc. the subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform. The business model comprises research and product development as well as the commercialisation of its activities. Our customers and partners include leading international pharmaceutical companies. WILEX AG is listed at the Frankfurt Stock Exchange. ISIN DE0006614720 / WKN 661472 / Symbol WL6. 
t WILEX Inc.
WILEX Inc. is a wholly owned US subsidiary of WILEX AG, Munich, Germany and manufactures, markets and sells serum based oncoprotein diagnostics and various biomarker tests under the brand name Oncogene Science. The product portfolio includes Enzyme-linked ImmunoSorbent Assays (ELISA) and immunohistochemical (IHC) assays. With the aim of supporting treatment regimens for cancer patients worldwide WILEX Inc. offers biomarker tests for measuring oncogenes, growth factor receptors (HER-2/neu, EGFr), proteases and protease inhibitors (uPA, PAI-1, TIMP-1), as well as markers of hypoxia (CA IX). In addition to the new CA IX IHC which is a class 1 IVD test, WILEX Inc. provides the only FDA-cleared IVD ELISA that measures the serum HER-2/neu level for the management and monitoring of patient care for women with metastatic breast cancer. WILEX Inc. is based in Cambridge, MA, USA and also provides GMP and ISO certified manufacturing services. More information is available on www.oncogene.com.